Cloud Pharmaceuticals Appoints Neurological Disorder Expert Jeff Vaught to Its Advisory Board
Former Chief Scientific Officer of Cephalon Offers Extensive Insight into the Development and Commercialization of Innovative Medicines
RESEARCH TRIANGLE PARK, N.C., Oct. 8, 2015 /PRNewswire/ -- Cloud Pharmaceuticals, Inc., a cloud-based drug design and development company, announced today the addition of Jeff Vaught, Ph.D., to its advisory board.
Dr. Vaught has more than 35 years of pharmaceutical R&D experience. Most recently, he served as the Chief Scientific Officer and Executive Vice President of Cephalon prior to its acquisition by TEVA Pharmaceuticals. In this capacity he had direct responsibilities for all non-clinical R&D managing over 400 scientists worldwide.
Previously, Dr. Vaught was Assistant Director, CNS Research, for the R.W.J. Pharmaceutical Research Institute (a Johnson & Johnson subsidiary), and served as central nervous system therapeutic area team leader for Johnson & Johnson. He also worked with Pfizer focusing on quality control earlier in his career. An accomplished researcher, Dr. Vaught has published more than 125 peer reviewed scientific articles in the field of neurobiology. He received his Ph.D. in pharmacology from the University of Minnesota.
"Jeff has extensive drug discovery and development experience and is a leader in the industry," says Ed Addison, Cloud Pharmaceuticals Chairman and CEO. "His expertise is of great value to Cloud Pharmaceuticals as we pursue our mission to improve health and well-being through the computational design and rapid development of low-cost and effective therapies."
About Cloud Pharmaceuticals, Inc.
Cloud Pharmaceuticals is committed to improving health and well-being through the computational design and rapid development of new medicines. Its Quantum Molecular Design process designs drug candidates that are qualified for development from the outset, enabling faster progress at lower cost and a higher success rate. The company partners at all stages of drug development – from discovery through the clinic – and is building an extensive product pipeline that spans a wide range of indications. For information visit www.cloudpharmaceuticals.com.
Available Topic Expert: Ed Addison
For information on the listed expert, click http://www.profnetconnect.com/edaddison.
SOURCE Cloud Pharmaceuticals, Inc.
Share this article